KromaTiD, Inc. is a Colorado-based, commercial stage genomic analysis company creating proprietary, unique products and services for the single-cell detection and quantitation of genomic structural variation associated with cellular engineering, genetic diseases, DNA repair, oncology and other applications.
The Company’s proprietary platform, directional Genomic Hybridization (dGH™), is a versatile, robust toolset with significant market traction. dGH provides insight into chromosomal rearrangements and complex structural variations through direct imaging of DNA structural properties. AI-driven analysis of thousands of such images enables single-cell structural genomic measurements that current leading technologies such as sequencing and hybridization arrays aren’t capable of. Even with single cell sequencing, de novo detection or quantitation of structural variants is not practical. As the only platform capable of true de novo detection of heterogenous and complex structural errors, KromaTiD’s dGH is an essential and powerful complement to sequencing-based assays. Only a combination of sequencing and dGH provides a full picture of on- and off-target editing-associated errors. The Company provides research services, as well as probes and kits, and can design and qualify assays for research use or CLIA testing.
dGH has been adopted in fields ranging from gene editing to biodosimetry. Our current customers include top US gene editing therapy companies, Top 20 Global Pharma companies, specialty biopharmas, and a number of institutional researchers with varied interests. We are interested in discussing partnerships and funding opportunities focused on cellular engineering, dGH assay development, structural biomarker screening and target discovery, undiagnosed diseases, and non-therapeutic areas of gene editing.”
hosted by Dr. Paul Monnier, Field Application Scientist
& Dr. Maria Milla, Life Sciences Application Scientist